BioTime is a leader in the emerging field of regenerative medicine whose foundation is based on pluripotent stem cell technology. Its current leadership position is in part based on the early nature ...
Given BioTime's history of over-promising and under-delivering, as we detailed in a prior article, we felt it would be wise to take a deep look at BioTime's pipeline of products and research and see ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has agreed to sell up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback